BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35462114)

  • 1. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X
    Yao W; Bai L; Wang S; Zhai Y; Sun SY
    Neoplasia; 2022 Jul; 29():100798. PubMed ID: 35462114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of the novel Bcl-2/Bcl-X
    Qian L; Vallega KA; Yao W; Wang D; Zhai Y; He X; Sun SY
    Mol Carcinog; 2022 Nov; 61(11):1031-1042. PubMed ID: 36066010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
    Lakhani NJ; Rasco D; Wang H; Men L; Liang E; Fu T; Collins MC; Min P; Yin Y; Davids MS; Yang D; Zhai Y
    Clin Cancer Res; 2024 Feb; 30(3):506-521. PubMed ID: 37971712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
    World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
    J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells.
    Takahashi H; Chen MC; Pham H; Matsuo Y; Ishiguro H; Reber HA; Takeyama H; Hines OJ; Eibl G
    Biochim Biophys Acta; 2013 Dec; 1833(12):2980-2987. PubMed ID: 23954445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
    Luo F; Lu FT; Qiu MZ; Zhou T; Ma WJ; Luo M; Zeng KM; Luo QY; Pan WT; Zhang L; Xia ZF; Zhang ZH; Cao JX; Zhao HY; Zhang L; Yang DJ
    Cell Death Dis; 2021 Aug; 12(8):772. PubMed ID: 34354046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells.
    Wang J; Yang D; Luo Q; Qiu M; Zhang L; Li B; Chen H; Yi H; Yan X; Li S; Sun J
    Int J Oncol; 2017 Aug; 51(2):563-572. PubMed ID: 28586007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
    Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
    Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-X
    Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
    Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
    Koehler BC; Scherr AL; Lorenz S; Urbanik T; Kautz N; Elssner C; Welte S; Bermejo JL; Jäger D; Schulze-Bergkamen H
    PLoS One; 2013; 8(10):e76446. PubMed ID: 24098503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
    Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
    Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma.
    Yi H; Qiu MZ; Yuan L; Luo Q; Pan W; Zhou S; Zhang L; Yan X; Yang DJ
    Cancer Med; 2020 Jun; 9(12):4197-4206. PubMed ID: 32346976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
    Scherr AL; Mock A; Gdynia G; Schmitt N; Heilig CE; Korell F; Rhadakrishnan P; Hoffmeister P; Metzeler KH; Schulze-Osthoff K; Illert AL; Boerries M; Trojan J; Waidmann O; Falkenhorst J; Siveke J; Jost PJ; Bitzer M; Malek NP; Vecchione L; Jelas I; Brors B; Glimm H; Stenzinger A; Grekova SP; Gehrig T; Schulze-Bergkamen H; Jäger D; Schirmacher P; Heikenwalder M; Goeppert B; Schneider M; Fröhling S; Köhler BC
    Cell Death Dis; 2020 Oct; 11(10):875. PubMed ID: 33070156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.